OUR SCIENCE
We will strive to become a global company that contributes to improving the quality of life.
Overview
Some cancers present challenges in treatment
Nearly 10 million patients for whom standard anticancer treatments fail die each year due to anticancer treatment resistance
-
Conventional anticancer resistance treatment
-
Tumor-targeted anticancer drugs
Current anticancer drugs target only tumor cells
-
Lack of individualized patient treatment
Absence of patient-specific selective treatment
Average treatment: low cure rate and high side effects
-
Single drug administration
Dosing a single-targeted treatment for a tumor: resistance persists
-
-
Next-generation anticancer resistance treatment
-
Tumor microenvironment targeting
Inhibition of cancer growth through regulation of stromal cells around the tumor
Inhibition of cancer growth through regulation of stromal cells around the tumor -
Individualized biomarker-targeted treatment for patients
Tracking tumor environmental biomarkers of individual patients
Individualized treatment: low side effects and high cure rate
-
Combined treatment administration
Overcoming resistance by administering tumor-targeted treatments and tumor microenvironment modulating drugs
-
Core Technology
Technology with high medical and commercial potential applicable to various anticancer drugs and carcinomas
-
- Cancer Drug Resistance
-
- Targeting ER Stress